INCLUSION CRITERIA:
1. \- Clinical Use Case 1: Liver disease staging in MASLD patients - Prediction model of fibrosis changes (progression and regression), with ability to distinguish between fast and non-fast fibrosis progression among MASLD patients.
* Age ≥18 years
* Diagnosis of MASLD confirmed by radiological imaging (any type: MR, CT, PET, VCTE, US, USE...) or histology (gold standard, following MASH SAF score)
* With at least one follow-up of minimum 1 year after diagnosis of MASLD, with radiological imaging or histology
2. \- Clinical Use case 2: MASLD and progression of cardiovascular diseases
* Age ≥18 years MASLD patients regardless of disease stage of severity (from simple steatosis to cirrhosis)
* Patients without known heart disease
* Cardiovascular assessment available
3.1- Clinical Use case 3-TIPS: Patients with cirrhosis and portal hypertension who receive TIPS placement.
* Age ≥18 years
* TIPS indication (Baveno VII), except pre-emptive and salvage TIPS.
* Recurrent variceal bleeding after failure of the usual pharmacological and endoscopic methods
* Refractory or recurrent ascites or difficult to treat
* Refractory Hydrothorax
* Patients with diagnosis of liver cirrhosis (based on laboratory parameters, clinical, endoscopic, radiological or histological findings), of any aetiology.
3.2.- Clinical Use Case 3-LT: Patients with cirrhosis and portal hypertension who received liver transplantation.
* Age ≥18 years
* All patients with cirrhosis (all aetiologies) who were transplanted
4.- Clinical Use Case 4: Prediction of cardiac complications due to HCC treatments\* (\*Note: includes surgical interventions, ablation, TACE, TARE, SIRT and immunotherapies)
* Age ≥18 years
* Diagnosis of HCC (any aetiology)
* Cross sectional imaging follow-up (any modality) of liver diseases 6 months after treatment
* Non-cirrhotic or no more than Child-Pugh B cirrhosis.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Patients without history of prior HCC
* Patients with a history of hypertension should be well controlled (\< 140/90 mmHg) on a regimen of antihypertensive therapy.
* With a minimum follow-up of two years or until death, after diagnosis of HCC
5.- Other populations (participation in control arms)
* Age ≥18 years
* Subjects presenting cardiac fibrosis, without a known MASLD diagnosis (as controls for use case 2)
EXCLUSION CRITERIA:
1. \- Clinical Use Case 1: Liver disease staging in MASLD patients - Prediction model of fibrosis changes (progression and regression), with ability to distinguish between fast and non-fast fibrosis progression among MASLD patients.
* Missing data on blood glucose, BMI and metabolic status.
* Patients who have received systemic chemotherapy
* Patients with hepatitis B (HBV) and hepatitis C (HCV), alcoholic liver disease (more than 5 years of drinking history, equivalent to alcohol volume ≥ 30g / D in male and ≥ 20g / D in female), drug-induced liver disease or autoimmune hepatitis.
* Subjects having a significant risk of bleeding (platelet \< 50x109 / L, prothrombin activity \< 50%)
* Presence of any other form of chronic liver, at the time of MASLD diagnosis.
2. \- Clinical Use case 2: MASLD and progression of cardiovascular diseases
* Association with another cause of liver disease
* History of hepatitis B or C
* Already known coronary artery disease
* History of cardiovascular events
3.1- Clinical Use case 3-TIPS: Patients with cirrhosis and portal hypertension who receive TIPS placement.
* Non-cirrhosis TIPS
* Portosinusoidal vascular disease
* Complete portal vein thrombosis
* Patients with surgical porto-caval shunts.
* Patients with evidence of current locally advanced or metastatic malignancy
* Patients with acute or chronic heart failure (New York Heart Association \[NYHA\]).
* Patients with chronic obstructive pulmonary disease GOLD grade III/IV
* Patients with chronic kidney disease requiring renal replacement therapy
* Patients with a known infection with human immunodeficiency virus (HIV) or have clinical signs and symptoms consistent with current HIV infection
* Patients with previous liver transplantation
* Patients lost to follow-up and therefore have an incomplete 1-year follow-up
3.2.- Clinical Use Case 3-LT: Patients with cirrhosis and portal hypertension who received liver transplantation.
* Patients who were transplanted due to acute liver failure.
* Patients who were already transplanted before (retransplant)
* Patients who are lost to follow-up in the first 5 years after liver transplant.
4.- Clinical Use Case 4: Prediction of cardiac complications due to HCC treatments\* (\*Note: includes surgical interventions, ablation, TACE, TARE, SIRT and immunotherapies)
* Mixed-tumor HCC based on radiological and/or pathological examination
* Uncontrolled inter-current illness or psychiatric illness or social situations that would limit compliance with study requirements.
* Subjects with history of another primary cancer
* Fully recovered from any prior surgery and/or radiation and none within 2 weeks of initiating treatment.
* Subjects with active hepatitis B or C on antiviral compounds may remain on such treatment, except for interferon.
* Subjects with diagnosis of tumor of mixed origin, either from radiological or biopsy report.
5.- Other populations (participation in control arms)
* Patients with diagnosis of MASLD
